Cancer Genetics Inc Receives Second Patent For Genomic Cervical Cancer Test; Strengthens Position Of FHACT

Cancer Genetics Inc, an emerging leader in DNA-based cancer diagnostics, announced today that it has received a second US patent covering its proprietary FISH-based HPV-Associated Cancer Test (FHACT®) for cervical cancer detection in patients. FHACT® is designed to assess change across four biomarkers indicating HPV-associated pre-cancers and cancers. Critically, FHACT® can help prevent unnecessary colposcopies and cervical biopsies, reducing costs and complications associated with these invasive procedures. "We are pleased to have received a second patent covering our proprietary FHACT® test. Having two patents for FHACT® further strengthens our position in this important and underserved category, and highlights the test's unique ability to revolutionize cervical cancer detection," said Panna Sharma, CEO of Cancer Genetics Inc. On October 21, the United States Patent and Trademark Office (USPTO) granted CGI a product design patent for the test's unique 4-probe combination. The additional patent granted today, November 11, covers the test's use on clinical patient samples, including cervical tissue specimen, remnant Pap-smear fluid, or liquid based cytology. The company believes that receiving patent protection for both the FHACT® test design and for its clinical application on patient samples underscores the novelty of the test, and sets a new standard in the field of cervical cancer diagnostics. FHACT was recently reviewed in Informa Healthcare's Expert Reviews by Dr. Jane Houldsworth. The review can be found in volume 14, number 8 of Expert Reviews, and is accessible online at informahealthcare.com. To learn more about FHACT®, please visit http://www.cgifhact.com.